These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18827907)

  • 21. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P; Allen E; Hollander P; Lewin A; Gabbay RA; Hu P; Bode B; Garber A;
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.
    Forst T; Larbig M; Hohberg C; Forst S; Diessel S; Borchert M; Roth W; Pfützner A
    Diabetes Obes Metab; 2010 May; 12(5):437-41. PubMed ID: 20415692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
    Papa G; Fedele V; Chiavetta A; Lorenti I; Leotta C; Luca S; Rabuazzo AM; Piro S; Alagona C; Spadaro L; Purrello F; Pezzino V
    Acta Diabetol; 2008 Mar; 45(1):53-9. PubMed ID: 18180864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH; Wascher T; Zackova V; Moeller J; Medding J; Szocs A; Mokan M; Mrevlje F; Regulski M
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can glycemic targets be achieved-- in particular with two daily injections of a mix of intermediate- and short-acting insulin?
    Raskin P
    Endocr Pract; 2006; 12 Suppl 1():52-4. PubMed ID: 16627381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
    Lavernia F
    Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin analog therapy: improving the match with physiologic insulin secretion.
    Freeman JS
    J Am Osteopath Assoc; 2009 Jan; 109(1):26-36. PubMed ID: 19193822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timely initiation of basal insulin.
    Riddle MC
    Am J Med; 2004 Feb; 116 Suppl 3A():3S-9S. PubMed ID: 15013454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.